|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hierarchical clustering by PR, ER and AR histoscores identified four EnOC subgroups (PR+/ER+, PR+/ER-, PR-/ER+ and PR-/ER-).
|
31495455 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Role of Androgen Receptor Signaling in Ovarian Cancer.
|
30791431 |
2019 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similar results have been obtained in prostate (regulation of enzymes involved in androgen synthesis and modulation of androgen receptor levels and activity) and ovary cancer.
|
30386380 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nanog interaction with the androgen receptor signaling axis induce ovarian cancer stem cell regulation: studies based on the CRISPR/Cas9 system.
|
29716628 |
2018 |
|
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous studies regarding the association between AR CAG repeat length and ovarian cancer risk reported inconsistent results.
|
28250337 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor is frequently expressed in various subtypes of ovarian cancers and androgen/AR signaling has been shown to promote proliferation, migration, and invasion of ovarian cancer cells.
|
27741511 |
2017 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Next, relative protein levels of AR and SGTA were measured in two sets of clinical samples: (1) 46 serous ovarian carcinomas (stages I-IV), 9 serous borderline tumors, and 11 benign ovarian tumors; and (2) 24 patient-matched stage III primary and metastatic serous ovarian tumors.
|
23443946 |
2013 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Anti-androgen use early in the course of ovarian cancer is more likely to be effective as these data suggest that androgen receptor expression decreases with exposure to chemotherapy and this may explain the low response rates seen in clinical trials of patients heavily pre-treated with multiple courses of chemotherapy.
|
22001143 |
2012 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized that AR CAG allele length is a modifier of clinical outcome in BRCA1/2 mutation positive women with ovarian cancer.
|
19818997 |
2010 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Rab25 correlated positively with AR expression supporting its role as an androgen responsive gene in ovarian cancer.
|
19623182 |
2009 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Previous studies of ovarian cancer and AR repeat polymorphisms have been inconsistent.
|
17372242 |
2007 |
|
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Androgen receptor gene methylation and exon one CAG repeat length in ovarian cancer: differences from breast cancer.
|
15545219 |
2004 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphic CAG repeat length within the androgen receptor gene: identification of a subgroup of patients with increased risk of ovarian cancer.
|
11956643 |
2002 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There is no conclusive evidence of association between AR CAG repeat size and breast or ovarian cancer risk in Jewish BRCA1/2 mutation carriers.
|
12404104 |
2002 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data suggest that AR allele length affects age of diagnosis of ovarian cancer, irrespective of BRCA mutation status.
|
11221880 |
2001 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
More recently, AR allele length was also inversely correlated with the histological grade of breast cancer, but no association was found between the AR-CAG polymorphism and the risk of either breast or ovary cancer.
|
11368874 |
2001 |
|
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor (AR) mRNA expression in HEY cells was compared to other ovarian cancer cell lines.
|
10706107 |
2000 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer.
|
10925355 |
2000 |
|
Malignant neoplasm of ovary
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Patterns of X-chromosome inactivation were determined by means of polymerase chain reaction amplification of the CAG-nucleotide repeat of the androgen receptor (AR) gene after methylation-sensitive restriction endonuclease digestion of blood mononuclear cell DNA from patients with invasive (n = 213) or borderline (n = 44) ovarian cancer and control subjects without a personal or family history of cancer (n = 50).
|
10050867 |
1999 |
|
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We have used X chromosome inactivation of the androgen receptor gene and microsatellite instability at four chromosomal loci to evaluate the clonal origin of 39 bilateral ovarian carcinomas.
|
7585507 |
1995 |